Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ADC Therapeutics SA (ADC Therapeutics) is a biotechnology company focused on the development of targeted therapies for cancer treatment. The company's main activities include advancing a portfolio of antibody-drug conjugates (ADCs) utilizing pyrrolobenzodiazepine technology and an exatecan-based payload. Its major product includes ZYNLONTA, a treatment for diffuse large B-cell lymphoma (DLBCL). ADC Therapeutics' products are primarily used by healthcare professionals in the oncology sector to treat various types of lymphomas and other cancers. The company collaborates with leading institutions through investigator-initiated trials to expand its clinical reach. It operates in the US and the UK. ADC Therapeutics is headquartered in Epalinges, Switzerland.
Headquarters
Switzerland
Address
Route De La Corniche 3b, Epalinges, 1066
Website
adctherapeutics.com
Telephone
41 21 6530200
No of Employees
188
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADCT (NYSE)
Revenue (2024)
$81.4M
14.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
9.6%
(2024 vs 2023)
Market Cap*
$161.5M
Net Profit Margin (2024)
XYZ
21.3%
(2024 vs 2023)
* As of and is in US$
ADC Therapeutics SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Zynlonta |
| ZYNLONTA (Loncastuximab Tesirine-lpyl): Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | |
| ADCT-602: Acute Lymphoblastic Leukemia | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | ADC Therapeutics SA | Roche Holding AG | Pfizer Inc | AbbVie Inc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | United States of America | United States of America | France |
| City | Epalinges | Basel | New York City | North Chicago | Paris |
| State/Province | - | Basel-Stadt | New York | Illinois | Ile-de-France |
| No. of Employees | 188 | 112,774 | 75,000 | 57,000 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Hug, Ph.D. | Vice Chairman | Executive Board | 2019 | 67 |
| Ameet Mallik | Chief Executive Officer; Director | Executive Board | 2022 | 53 |
| Jose Carmona | Chief Financial Officer | Senior Management | 2022 | 54 |
| Peter Graham | Chief Legal Officer | Senior Management | 2024 | 59 |
| Kimberly Pope | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer